Dr. Reddy’s US generics enterprise drags Q1 earnings, eyes weight-loss drug launch in 87 international locations
[ad_1] Dr Reddy’s Laboratories Ltd’s US generics enterprise slumped within the June quarter because it confronted value erosion in key merchandise like gRevlimid used to deal with most cancers. US generics income declined 11% year-on-year and 4% sequentially to ₹3,412 crore within the first quarter of FY26, based on earnings introduced on Wednesday. The enterprise … Read more